Coherus Oncology financials
$1.18+3.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M | $475.8M | $356.1M | $0.00 | $1.6M | $190.1M |
| Gross profit | $28.4M | $17.7M | $98.3M | $141.0M | $269.0M | $438.2M | $339.0M | $0.00 | $1.6M | $190.1M |
| Gross margin | 67.2% | 66.9% | 38.2% | 66.8% | 82.4% | 92.1% | 95.2% | — | 100.0% | 100.0% |
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M | $156.3M | $107.8M | -$204.4M | -$232.1M | -$115.9M |
| Net income | $168.0M | $28.5M | -$237.9M | -$291.8M | -$287.1M | $132.2M | $89.8M | -$209.3M | -$238.2M | -$127.3M |
| Net margin | 398.4% | 108.0% | −92.5% | −138.2% | −87.9% | 27.8% | 25.2% | — | −15306.6% | −67.0% |
| Diluted EPS | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 | $1.62 | $1.23 | $-3.22 | $-4.48 | $-3.04 |
| EBITDA | -$177.2M | -$194.4M | -$199.4M | -$253.2M | -$260.4M | $159.2M | $111.0M | -$201.2M | -$228.7M | -$112.9M |
| Operating cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M | $154.1M | $28.4M | -$159.3M | -$200.3M | -$252.5M |
| Free cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$38.7M | $146.9M | $26.5M | -$160.1M | -$204.9M | -$259.1M |
| Diluted shares | 117.1M | 114.6M | 94.2M | 77.6M | 75.4M | 83.5M | 73.2M | 65.0M | 53.1M | 41.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $88.9M | $126.0M | $102.9M | $63.5M | $417.2M | $541.2M |
| Short-term investments | $83.2M | $0.00 | $14.9M | $128.1M | — | — |
| Total debt | $37.1M | $228.2M | $473.4M | $471.1M | $408.3M | $377.4M |
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M | $841.6M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M | $560.7M |
| Shareholders' equity | $61.0M | -$132.0M | -$193.4M | -$137.4M | $97.7M | $281.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology